CAM
ABVX icon

Cresset Asset Management’s Abivax ABVX Stock Holding History

Cresset Asset Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,174
Closed -$563K – 1655
2025
Q4 		$563K Buy
+4,174
New +$455K ﹤0.01% 1016

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

Cresset Asset Management's ABVX Position: Q1 2026 in Review

Cresset Asset Management sold out of Abivax (ABVX) in Q1 2026, closing a stake of 4,174 shares — an estimated $563K sold.

Cresset Asset Management first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $563K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Cresset Asset Management reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Cresset Asset Management sold 4,174 Abivax shares in Q1 2026, an estimated $563K.
  • Cresset Asset Management first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
  • Cresset Asset Management's Abivax position peaked at $563K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.